drugset / Trial / NCT00415779
ZANTE: Zometa and Taxotere in Hormone Refractory Prostate Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This phase I trial is studying the side effects and best dose of docetaxel when given with zoledronic acid in patients with bone metastasis from prostate cancer that has not responded to hormone therapy.
Timeline
- Start
- 2006-07
- Primary completion
- 2008-12
- Completion
- 2009-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 30 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 40 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 50 mg/m2 | Intravenous |
| Background | Zoledronic acid | Other / unclassified | 2 mg | Intravenous |